Choose Your News
Loading...
Chief Executive Officer... [Read More]
President, CE... [Read More]
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher by $5.75, or 14 percent, at $46.83 in Wednesday's session. The catalyst for the rally ... [Read More]
Sept 6- Sarepta Therapeutics Inc's shares surged on Wednesday after the results of a trial on its drug to treat a fatal muscle-wasting disease showed. [Read More]
Sept 6- Sarepta Therapeutics Inc's shares jumped about 15 percent on Wednesday after the company's drug to treat patients with a form of a fatal. [Read More]
Sarepta Therapeutics Inc. ... [Read More]
Thumbnail
CAMBRIDGE, Mass., Aug. 31, 2017-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development. [Read More]
Thumbnail
CAMBRIDGE, Mass., July 24, 2017-- Sarepta Therapeutics, Inc., a U.S. commercial-stage biopharmaceutical company focused on the discovery and. [Read More]
Executive Director-Corporate Affairs... [Read More]
Sarepta Therapeutics Inc. ... [Read More]
Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy... [Read More]
Clinigen Group plc's (AIM: CLIN, 'Clinigen') Idis Managed Access division and Sarepta Therapeutics Inc. (NASDAQ: SRPT) have initiated a Managed... [Read More]
Expected Earnings Release: 07/19/2017, After-hours Avg. Extended-Hours Dollar Volume: $5,119,028 Sarepta Therapeutics, Inc. ( SRPT ) is due to issue. [Read More]
Loading...
Preview